aTYR Pharma
aTYR Pharma's revenue fell 19.1% to $0 million in fiscal 2025. Its operating margin was −40,856.3%, down from −28,899.6% a year earlier. Free cash flow was −$62 million. The diluted share count rose 25.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What aTYR Pharma does
aTYR Pharma is a clinical stage biotechnology company. It has no products on the market. It is developing new drugs for fibrosis (scarring) and inflammation, based on its research into tRNA synthetases, ancient proteins found in every human cell.
Its lead drug candidate is efzofitimod, a biologic given by infusion for interstitial lung disease, a group of disorders that can inflame and scar the lungs. The company tested it in a large Phase 3 trial in pulmonary sarcoidosis. The trial did not meet its main goal, which was a lower daily steroid dose at week 48, though the company points to gains on some other measures. It plans to meet the FDA to decide what comes next. A smaller Phase 2 trial in lung disease linked to systemic sclerosis (scleroderma) is also under way.
With no product sales, aTYR depends on its collaboration with Kyorin Pharmaceutical, which holds the rights to efzofitimod in Japan, and on outside funding. It relies on contract manufacturers and research organizations to make the drug and run its trials. It had 58 employees at the end of 2025, most of them in research, clinical and regulatory roles.
Its biggest risks, as it describes them
- Clinical trials may fail or be delayed, as the main goal of its Phase 3 sarcoidosis trial was missed.
- It may never win regulatory approval for efzofitimod or other candidates, or sell them successfully.
- It relies on outside companies to make its drug candidates and run its clinical trials.
- It may be unable to protect its patents, or may be accused of infringing the patents of others.
- Its collaborations, such as the Kyorin agreement in Japan, may not succeed.
Income statement
aTYR Pharma lost money in fiscal 2025: a net loss of $74 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 108 | 66 | 98 | 72 | 79 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | −859.3x | −319.3x | −495.7x | −825.8x |
| Current ratio | 18.9x | 5.8x | 6.3x | 5.5x | 5.3x |
| Quick ratio | 18.9x | 5.8x | 6.3x | 5.5x | 5.3x |
Cash flow
Projections
Project aTYR Pharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What aTYR Pharma says to expect
- Cash runway: current cash position
Based on its current cash and operating expense forecast and plans, the Company anticipates that this cash position will be sufficient to fund the Company’s current operations into late 2028.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $50,000 of aTYR Pharma shares on the open market, and 3 insiders sold $6,293.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 27, 2026 | Paul SchimmelDirector | Bought | 100,000 | $0.50 | $50,000 | Form 4 |
| Feb 4, 2026 | Sanjay ShuklaPresident and CEO, Director | Sold | 3,745 | $0.98 | $3,670 | Form 4 |
| Feb 4, 2026 | Jill Marie BroadfootChief Financial Officer | Sold | 1,558 | $0.98 | $1,527 | Form 4 |
| Feb 4, 2026 | Nancy DenyesGeneral Counsel | Sold | 1,118 | $0.98 | $1,096 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −10,701.7% | −29,473.4% | −32,683.9% |
| Altman Z'' | −7.85 | −15.37 | −19.52 |
| Accruals ratio | −15.9% | 4.7% | −12.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | — | — | — |
Compare
Put aTYR Pharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| aTYR Pharma | FY25 | −19.1% | −40,856.3% | −32,664.7% | — | — | — | |
| BioRestorative Therapies | FY25 | −10.3% | −4,350.1% | −3,031.7% | — | — | — | Compare |
| Connect Biopharma | FY25 | −99.8% | −90,740.6% | −80,687.5% | — | — | 1 | Compare |
| Cardiff Oncology | FY25 | −13.2% | −8,256.3% | −6,402.5% | — | — | 2 | Compare |
| PMGC Holdings | FY25 | — | — | −1,080.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | — | 0 | 10 | 0 | 10 | 0 | 0 | 0 |
| Revenue growth | — | — | — | — | 2,377.5% | −100.0% | — | −96.6% | −33.4% | −19.1% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 43 | 30 | 20 | 14 | 17 | 23 | 43 | 42 | 54 | 60 |
| Operating income | −58 | −47 | −33 | −23 | −16 | −34 | −46 | −55 | −68 | −78 |
| Net income | −58 | −48 | −34 | −16 | −16 | −34 | −45 | −50 | −64 | −74 |
| Diluted EPS (US$) | −2.44 | −26.13 | −16.11 | −7.03 | −1.77 | −1.77 | −1.60 | −0.94 | −0.86 | −0.80 |
| Diluted shares (millions) | 24 | 2 | 2 | 3 | 9 | 19 | 28 | 54 | 74 | 93 |
| Cash flow | ||||||||||
| Cash from operations | −53 | −42 | −31 | −20 | −15 | −33 | −42 | −33 | −69 | −62 |
| Capital expenditure | 1 | 1 | 1 | 0 | 0 | 0 | 2 | 4 | 0 | 0 |
| Free cash flow | −53 | −44 | −32 | −20 | −16 | −33 | −44 | −37 | −69 | −62 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 5 | 7 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 5 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 72 | 85 | 50 | 31 | 32 | 108 | 66 | 98 | 72 | 79 |
| Debt incl. finance leases | 10 | 20 | 16 | — | — | — | — | — | — | — |
| Total assets | 80 | 89 | 53 | 36 | 39 | 116 | 96 | 121 | 97 | 93 |
| Total liabilities | 18 | 25 | 19 | 15 | 7 | 6 | 24 | 30 | 27 | 26 |
| Shareholders' equity | 63 | 64 | 34 | 21 | 32 | 109 | 72 | 91 | 70 | 68 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | −5,445.0% | −152.2% | — | −446.8% | −15,557.8% | −28,899.6% | −40,856.3% |
| Net margin | — | — | — | −3,844.6% | −155.2% | — | −436.5% | −14,274.5% | −27,243.8% | −39,009.5% |
| Free cash flow margin | — | — | — | −4,761.1% | −148.3% | — | −419.1% | −10,605.1% | −29,440.0% | −32,664.7% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | 2,229.2% | — | — | −10,701.7% | −29,473.4% | −32,683.9% |
| Return on capital | −368.4% | — | — | — | — | — | — | — | — | — |
| Return on equity | −65.1% | −75.9% | −70.5% | −59.2% | −61.4% | −47.9% | −50.2% | −62.2% | −79.7% | −107.8% |
| Return on assets | −55.0% | −56.8% | −48.6% | −36.5% | −43.3% | −43.8% | −42.9% | −46.6% | −58.9% | −78.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |